Mike Levine of Dealbreaker reports, biz-tech-bitchily: It seems that California biopharma company Immunosyn has been a little more optimistic about the prospects for its blockbuster drug than would be warranted by the facts. Specifically facts such as (1) the FDA has blocked clinical trials in the U.S., (2) there are no clinical trials likely elsewhere, […]